PMID- 9128417
OWN - NLM
STAT- MEDLINE
DCOM- 19970707
LR  - 20151119
IS  - 0300-9157 (Print)
IS  - 0300-9157 (Linking)
VI  - 37
IP  - 1
DP  - 1997 Feb
TI  - [Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in 
      knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis].
PG  - 3-8
AB  - The objective of this study is to determine the levels of matrix 
      metalloproteinase-3 (MMP-3) and urokinase-type plasminogen activator (uPA) in 
      knee synovial fluids from patients with rheumatoid arthritis (RA) and 
      osteoarthritis (OA). Knee synovial fluids were collected from patients with RA 
      and OA. Concentrations of MMP-3 were determined by enzyme immunoassay using a 
      pair of monoclonal antibodies against human proMMP-3, and activities of uPA were 
      measured by immunocapture assay using a polyclonal antiserum against human uPA. 
      The median concentration of MMP-3 in synovial fluids was 97.5 +/- 82.6 
      micrograms/ml (range 1.06-336 micrograms/ml) for RA group and 20.5 +/- 11.3 
      micrograms/ml (range 6.19-42.8 micrograms/ml) for OA group. Levels of MMP-3 were 
      significantly higher in RA group than in OA group. The median activity of uPA in 
      synovial fluids was 0.053 +/- 0.052 i.u./ml (range 0.003-0.187 i.u./ml) for RA 
      group and 0.072 +/- 0.059 i.u./ml (range 0.006-0.169 i.u./ml) for OA group. No 
      significant difference of uPA activity was observed between RA and OA group. 
      Significant correlation of the levels of MMP-3 with those of uPA was observed in 
      RA group, however not in OA group. The increased levels of MMP-3 in synovial 
      fluids in RA group may reflect an elevated matrix degrading activity due to joint 
      inflammation. The significant correlation of MMP-3 with uPA in RA group suggests 
      that MMP-3 could degrade cartilage matrix more actively in conjunction with 
      PA-plasmin system than MMP-3 alone.
FAU - Gotoh, H
AU  - Gotoh H
AD  - Department of Orthopaedic Surgery, Self Defense Force Yokosuka Hospital, 
      Yokosuka-city.
FAU - Yamada, H
AU  - Yamada H
FAU - Yoshihara, Y
AU  - Yoshihara Y
FAU - Kikuchi, T
AU  - Kikuchi T
FAU - Obata, K
AU  - Obata K
FAU - Shinmei, M
AU  - Shinmei M
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Ryumachi
JT  - Ryumachi. [Rheumatism]
JID - 0153217
RN  - 0 (Biomarkers)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/*enzymology/physiopathology
MH  - Biomarkers/analysis
MH  - Bone Resorption
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*analysis
MH  - Middle Aged
MH  - Osteoarthritis/*enzymology/physiopathology
MH  - Plasminogen Activators/*analysis
MH  - Synovial Fluid/*enzymology
MH  - Urokinase-Type Plasminogen Activator/*analysis
EDAT- 1997/02/01 00:00
MHDA- 1997/02/01 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/02/01 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
PST - ppublish
SO  - Ryumachi. 1997 Feb;37(1):3-8.